Comparison
Cagrilintide vs. CJC-1295
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Growth
CAS no.
1415456-99-3
no data
Molecular weight
4253.7 g/mol
3647.3 g/mol
Half-life
168 h
144 h
Sequence
KCNTATCATQRLANFLVRSSNNLGPVLPPTNVGSNTYYADAIFTNSYRKVLGQLSARKLLQDIMSR-DACMechanism of action
Cagrilintide
Cagrilintide binds amylin receptors (AMY1, AMY3, formed by the calcitonin receptor plus RAMP proteins). Activation delays gastric emptying, inhibits postprandial glucagon secretion and modulates central satiety signalling via area postrema neurons. An acyl modification enables albumin binding and thereby weekly dosing.
CJC-1295
Synthetic analogue of growth-hormone-releasing hormone (GHRH), modified for extended half-life via a Drug Affinity Complex (DAC) binding to albumin. Acts on the pituitary GHRH receptor and stimulates endogenous growth-hormone release.
Evidence base
Highest evidence
Human RCT
Human trial
Studies
4
3
of which in humans
3
2
Effects recorded
3
3
Open conflicts
0
1
Documented adverse events
1
3